Autolus Therapeutics plc American Depositary Share (AUTL)

Autolus Therapeutics presented promising Phase 1 clinical trial data for obe-cel, a CAR T cell therapy targeting severe refractory systemic lupus erythematosus, showing high remission rates and potential for meaningful clinical impact.

4 analysts have expressed a variety of opinions on Autolus Therapeutics (NASDAQ:AUTL) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullis...

Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.

The biopharmaceutical company announced the pricing of a secondary stock offering.

Blackstone Inc. is investing as much as $250 million in U.K. biotechnology company Autolus Therapeutics PLC to fund the final stages of development of a new therapy to treat a serious form of leukemia, the companies said.